loading...| Preferred Name |
entecavir |
|
| Synonyms |
Baraclude ETV |
|
| Definitions |
A synthetic analog of 2-deoxyguanosine with antiviral activity against hepatitis B virus (HBV). Entecavir is activated in vivo to a 5-triphosphate metabolite. In turn, the triphosphate form competes with the natural substrate deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. The incorporation of the activated triphosphate metabolite of entecavir inhibits the reverse transcriptase (RT) viral RNA-dependent HBV DNA polymerase and, so, the replication of viral DNA and transcription. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65513" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65513" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000617986 |
|
| altLabel |
Baraclude ETV |
|
| CAS Registry |
209216-23-9 |
|
| cui |
C1568876 C0971023 |
|
| DATE FIRST PUBLISHED |
2008-10-20 |
|
| Date last modified |
2016-02-05 |
|
| definition |
A synthetic analog of 2-deoxyguanosine with antiviral activity against hepatitis B virus (HBV). Entecavir is activated in vivo to a 5-triphosphate metabolite. In turn, the triphosphate form competes with the natural substrate deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. The incorporation of the activated triphosphate metabolite of entecavir inhibits the reverse transcriptase (RT) viral RNA-dependent HBV DNA polymerase and, so, the replication of viral DNA and transcription. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65513" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65513" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C65513 |
|
| notation |
CDR0000617986 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
entecavir |
|
| tui |
T114 T121 |